Outpatient continuous inotrope infusion as an adjunct to heart failure therapy in Duchenne muscular dystrophy

被引:12
|
作者
Cripe, Linda H. [1 ]
Barber, Brent J.
Spicer, Robert L.
Wong, Brenda L.
Weidner, Norbert
Benson, D. Woodrow
Markham, Larry W.
机构
[1] Cincinnati Childrens Hosp Med Ctr, Div Cardiol, Cincinnati, OH 45229 USA
[2] Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA
[3] Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati, OH 45229 USA
[4] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH 45229 USA
[5] Univ Arizona, Coll Med, Div Cardiol, Tucson, AZ USA
关键词
inotropes; dobutamine; milrinone; Duchenne muscular dystrophy;
D O I
10.1016/j.nmd.2006.07.021
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We report the use of continuous intravenous inotrope infusion as a palliative management strategy for the treatment of symptomatic, refractory, end stage cardiac dysfunction in patients with Duchenne muscular dystrophy. Milrinone and/or dobutamine administered by continuous intravenous infusion provided symptomatic and objective cardiovascular improvement up to 30 months in 3 individuals with Duchenne muscular dystrophy and severe dilated cardiomyopathy. Continuous inotrope infusion should be considered a practical treatment strategy for end stage cardiac dysfunction in Duchenne muscular dystrophy patients when cardiac transplantation is not a viable option. (C) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:745 / 748
页数:4
相关论文
共 50 条
  • [31] Problems and potential for gene therapy in Duchenne muscular dystrophy
    Kakulas, BA
    NEUROMUSCULAR DISORDERS, 1997, 7 (05) : 319 - 324
  • [32] Prophylactic oral bisphosphonate therapy in duchenne muscular dystrophy
    Srinivasan, Ramesh
    Rawlings, David
    Wood, Claire L.
    Cheetham, Tim
    Moreno, Aura Cecilia Jimenez
    Mayhew, Anna
    Eagle, Michelle
    Guglieri, Michela
    Straub, Volker
    Owen, Catherine
    Bushby, Kate
    Sarkozy, Anna
    MUSCLE & NERVE, 2016, 54 (01) : 79 - 85
  • [33] Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy
    Daniel P. Judge
    David A. Kass
    W. Reid Thompson
    Kathryn R. Wagner
    American Journal of Cardiovascular Drugs, 2011, 11 : 287 - 294
  • [34] CORTICOSTEROID-THERAPY IN DUCHENNE MUSCULAR-DYSTROPHY
    KHAN, MA
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1993, 120 (01) : 8 - 14
  • [35] Preclinical Studies for Gene Therapy of Duchenne Muscular Dystrophy
    Odom, Guy L.
    Banks, Glen B.
    Schultz, Brian R.
    Gregorevic, Paul
    Chamberlain, Jeffrey S.
    JOURNAL OF CHILD NEUROLOGY, 2010, 25 (09) : 1149 - 1157
  • [36] Rotating inotrope therapy in a pediatric population with decompensated heart failure
    Ryerson, Lindsay M.
    Alexander, Peta M. A.
    Butt, Warwick W.
    Shann, Frank A.
    Penny, Daniel J.
    Shekerdemian, Lara S.
    PEDIATRIC CRITICAL CARE MEDICINE, 2011, 12 (01) : 57 - 60
  • [37] Imaging the heart to detect cardiomyopathy in Duchenne muscular dystrophy: A review
    Power, Lisa C.
    O'Grady, Gina L.
    Hornung, Tim S.
    Jefferies, Craig
    Gusso, Silmara
    Hofman, Paul L.
    NEUROMUSCULAR DISORDERS, 2018, 28 (09) : 717 - 730
  • [38] Genetic correction strategies for Duchenne muscular dystrophy and their impact on the heart
    Johnston, Jamie R.
    McNally, Elizabeth M.
    PROGRESS IN PEDIATRIC CARDIOLOGY, 2021, 63
  • [39] Corticosteroid Therapy for Duchenne Muscular Dystrophy: Improvement of Psychomotor Function
    Sato, Yuko
    Yamauchi, Akemi
    Urano, Mari
    Kondo, Eri
    Saito, Kayoko
    PEDIATRIC NEUROLOGY, 2014, 50 (01) : 31 - 37
  • [40] Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy
    Hauser, MA
    Amalfitano, A
    KumarSingh, R
    Hauschka, SD
    Chamberlain, JS
    NEUROMUSCULAR DISORDERS, 1997, 7 (05) : 277 - 283